ARISE is conducting a questionnaire-based study,...
Home / News
An interview with a Sickle cell disease patient living in Portugal
Living with a rare disease like sickle cell...
ARISE newsletter: February 2024
Read the ARISE newsletter: February 2024
Gene Therapy for Sickle Cell Disease
Gene Therapies for Sickle Cell Disease available
ARISE newsletter: December 2023
Read the ARISE newsletter: December 2023
ARISE newsletter: November 2023
Read the ARISE newsletter: November 2023
ARISE newsletter: October 2023
Read the ARISE newsletter: October 2023
New training material available: ARISE webinars on iron overload and MRI
ARISE highly appreciates the wide participation in the ARISE webinars on iron overload and the use of the Magnetic Resonance Imaging in Sickle Cell Disease
ARISE newsletter: August 2023
Read the ARISE newsletter: August 2023
New article just published
The article Global Burden of Transfusion in Sickle Cell Disease is now available.
ARISE newsletter: July 2023
Read the ARISE newsletter: July 2023
ARISE newsletter: June 2023
Read the ARISE newsletter: June 2023
New review on voxelotor for the treatment of hemolytic anemia
A new expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: ‘bridging the gap between laboratory data and patient related outcomes’ has just been published
ARISE newsletter: May 2023
Read the ARISE newsletter: May 2023
Third International Summit on Human Genome Editing (6-8 March 2023)
The Third International Summit on Human Genome Editing took place in London, UK on March 6-8, 2023.
SAVE THE DATE: Sickle Cell & Thalassaemia course
A two-day training course on Sickle Cell Disease and Thalassaemia will run virtually on 17th-18th October 2022. The course is organised by South Thames Sickle Cell & Thalassemia Network.
SAVE THE DATE: ITHANET virtual information day
The ITHANET virtual information day will be held virtually on September 29th 14:00 – 17:00 GMT+3.
In remembrance of Prof Kwaku Ohene-Frempong
Dear colleagues, friends, and the Sickle Cell Disease community, with profound sadness, we learned of the passing of Prof Kwaku Ohene-Frempong a giant in the Sickle Cell Disease field
Oxbryta received CHMP positive opinion for SCD
The Committee for Medicinal Products for Human Use at the EMA adopted a positive opinion recommending marketing authorization for Oxbryta® for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
The International Hemoglobinopathy Research Network: new article published
ARISE consortium, as member of the International Hemologlobinopathy Research Network – INHERENT is excited to announce a paper recently published in the American Journal of Hematology.
